| CISL2304 | PMBCL | Real-world outcomes of patients with primary mediastinal large B-cell lymphoma in Korea: A multicenter, retrospective analysis
| PMBCL | Registry | Retrosp | 150 | Ongoing | | |
| CISL2303 | VR2 | A phase 1/2 study of the combination of venetoclax, rituximab and lenalidomide for relapsed or refractory primary central nervous system lymphoma | CNS | Salvage | Phase 1/2 | 35 | Preparing | 3 | 1 |
| CISL2302 | ZRICE | Phase I/II study of Zanubrutinib in combination with Rituximab, Ifosfamide, Carboplatin, and Etoposide [ZR-ICE] in relapsed/refractory diffuse large B cell lymphoma | DLBCL | Salvage | Phase 1/2 | 72 | Ongoing | 12 | 1 |
| CISL2301 | SIENA | Phase 1/2 study of Selinexor in combination with ICE-D in patients with secondary CNS involving relapsed or refractory B-cell non-Hodgkin lymphoma | B-NHL | Salvage | Phase 1/2 | 35 | Ongoing | 3 | 1 |
| CISL2209 | PCNSL-R2P | Chemotherapy-free salvage therapy with rituximab, lenalidomide, and poseltinib for the treatment of relapsed or refractory primary central nervous system lymphoma | CNS | Salvage | Phase 2 | 29 | Ongoing | 5 | 1 |
| CISL2208 | DuoFOLK | Duodenal-type Follicular Lymphoma in Korean Population: A Multicenter Study | FL | Registry | Cohort | 245 | Ongoing | 42 | 8 |
| CISL2207 | BRIF | Retrospective analysis of opportunistic infectious events in Lymphoma patients who were treated with bendamustine plus anti-CD20 monoclonal antibody | B-NHL | 1st-line | Retrosp | 150 | Closed | 220 | 18 |
| CISL2206 | TARANIS | Phase II study of Concurrent Tislelizumab and Radiotherapy for treatment-naive, newly diagnosed low-risk extranodal NK/T-cell lymphoma, nasal type | NK/T | 1st-line | Phase 2 | 38 | Ongoing | 14 | 6 |
| CISL2205 | NKPEM | A multi-center retrospective study of pembrolizumab in patients with relapsed or refractory extranodal NK/T-cell lymphoma | NK/T | Salvage | Retrosp | 30 | Published | 31 | 11 |
| CISL2204 | BRM | A randomized phase II trial comparing rituximab/bendamustine (RB) alternating with rituximab/bendamustine/cytarabine (RBAC) with RB as induction therapy in elderly patients with newly diagnosed and transplant-ineligible mantle cell lymphoma | MCL | 1st-line | Phase 2R | 90 | Ongoing | 6 | 5 |
| CISL2203 | GPL | Phase II study of Glofitamab, Poseltinib and Lenalidomide in patients with relapsed/refractory diffuse large B cell lymphoma | DLBCL | Salvage | Phase 2 | 102 | Ongoing | 88 | 19 |
| CISL2202 | ACANTHUS | Multicenter, open label, phase I/II study of azacitidine-CHOP for patients with nodal T-cell lymphoma with T-follicular helper phenotype | TFHL | 1st-line | Phase 1/2 | 41 | Ongoing | 19 | 8 |
| CISL2201 | PCNSL-LEM | Phase II trial of Lenalidomide maintenance after high-dose methotrexate-based immunochemotherapy in patients with primary central nervous system lymphoma
| CNS | Maintenance | Phase 2 | 31 | Ongoing | 28 | 7 |
| CISL2104 | LARCH | Phase II study of lenalidomide-R-CHOP for patients with diffuse large B cell lymphoma who are at high risk of central nervous system relapse | DLBCL | 1st-line | Phase 2 | 100 | Ongoing | 95 | 11 |
| CISL2103 | BIOPB | Impact of cell-of-origin and dual expression/translocation of MYC and BCL2/BCL6 on the risk of CNS relapse in patients with primary breast DLBCL: A multicenter, retrospective, biologic correlative study | DLBCL | Registry | Retrosp | 63 | Closed | 27 | 11 |
| CISL2102 | ICING | Phase II study of Isatuximab and Cemiplimab in relapsed or refractory naturalkiller/T-cell lymphoid malignancy | NK/T | Salvage | Phase 2 | 37 | Ongoing | 38 | 7 |
| CISL2101 | RAINBOW | Prospective multi-center cohort study of newly diagnosed primary central nervous system lymphoma patients: Evaluation of tumor microenvironment by brain biopsy with multiplex immunohistochemistry | CNS | Registry | Cohort | 200 | Ongoing | 12 | 1 |
| CISL2004 | ICON | A prospective cohort of ibrutinib treatment for relapsed or refractory CLL with next-generation sequencing (NGS) assessment | CLL | Registry | Cohort | 30 | Ongoing | 31 | 7 |
| CISL2003 | BRIDGE | Brentuximab vedotin plus cisplatin, cytarabine, and dexamethasone in patients with relapsed or refractory Hodgkin’s lymphoma who are eligible for transplant. | HL | Salvage | Phase 2 | 30 | Ongoing | 3 | 3 |
| CISL2002 | OBICOM | Multicenter prospective Cohort study of combined chemotherapy with obinutuzumab and chlorambucil for elderly patients with chronic lymphocytic leukemia based on NGS assessment | CLL | Registry | Cohort | 31 | Ongoing | 34 | 9 |
| CISL2001 | IBER | Clinical efficacy and safety of IBER salvage treatment followed by ibrutinib maintenance for transplant-ineligible patients with relapsed or refractory primary central nervous system lymphoma(PCNSL) | CNS | Salvage | Phase 2 | 30 | Closed | 30 | 9 |
| CISL1913 | BR-MCL | Bendamustine plus rituximab for mantle cell lymphoma: a multicenter retrospective analysis | MCL | Salvage | Retrosp | 40 | Published | 37 | 8 |
| CISL1912 | D-GEMOX | Decitabine with Gemcitabine, Oxaliplatin for relapsed/refractory peripheral T cell lymphoma | PTCL | Salvage | Phase 2 | 66 | Ongoing | 14 | 6 |
| CISL1911 | HOLY | Multicenter retrospective study of elderly Hodgkin lymphoma | HL | Registry | Retrosp | 500 | Ongoing | 181 | 17 |
| CISL1910 | MCLRR | Ibrutinib for relapsed or refractory mantle cell lymphoma: multicenter retrospective analysis | MCL | Salvage | Retrosp | 100 | Published | 88 | 18 |
| CISL1909 | FLPOD24 | Clinical outcomes of Early-progressed follicular lymphoma in Korea : A multicenter, retrospective analysis | FL | Registry | Retrosp | 80 | Published | 76 | 16 |
| CISL1908 | COGETB | Prospective cohort study for genomic evaluation in patients with diffuse large B cell lymphoma after first relapse or progression (COGET-B) | DLBCL | Registry | Cohort | 200 | Closed | 41 | 8 |
| CISL1907 | COSMOS | Prospective, multicenter, open-labeled, phase I/II study of the efficacy and safety of copanlisib (BAY 80-6946) and gemcitabine combination | PTCL | Salvage | Phase 2 | 28 | Published | 28 | 8 |
| CISL1906 | KBPDCN | Blastic plasmacytoid dendritic cell neoplasm in Korean population: A multicenter study | BPDCN | Registry | Retrosp | 40 | Closed | 36 | 11 |
| CISL1905 | RRT-Allo | Allogeneic Stem Cell Transplantation with 3-days Busulfan plus fludarabine as Conditioning in Patients with Relapsed or Refractory T-, NK/T-cell lymphomas | PTCL | Salvage | Phase 2 | 34 | Ongoing | 20 | 10 |
| CISL1904 | AP MCLR | Asia-Pacific Multinational Registry of Mantle cell lymphoma | MCL | Registry | Cohort | 250 | Ongoing | 120 | 43 |
| CISL1903 | R2A | Phase II trial of Acalabrutinib with rituximab and lenalidomide in relapsed/refractory B-cell non-Hodgkin lymphoma | B-NHL | Salvage | Phase 2 | 66 | Closed | 64 | 13 |
| CISL1902 | HOT | Multicenter Prospective Cohort Study of Hodgkin Lymphoma | HL | Registry | Cohort | 300 | Ongoing | 129 | 15 |
| CISL1901 | EPIC | A Phase II Study of Epigenetic Priming Using Azacitidine Followed by R-GDP in Patients with Transplant-Ineligible Relapsed/Refractory DLBCL | DLBCL | Salvage | Phase 2 | 27 | Ongoing | 15 | 7 |
| CISL1804 | RELOAD | Lenalidomide plus reduced dose R-CHOP chemotherapy followed by lenalidomide maintenance therapy in elderly patients with DLBCL | DLBCL | 1st-line | Phase 2 | 68 | Closed | | |
| CISL1803 | BRAVO | A multi-center and non-interventional registry of Brentuximab Vedotin in patients with relapsed or refractory CD30+ lymphoma
| CD30+ | Salvage | Cohort | 150 | Ongoing | 85 | 12 |
| CISL1802 | FIXATION | A phase 2 study of ixazomib maintenance treatment for newly diagnosed mantle cell lymphoma | MCL | Maintenance | Phase 2 | 30 | Ongoing | 30 | 9 |
| CISL1801 | LEMONT | Phase II study of Lenalidomide Maintenance after Salvage therapy in patients with relapsed and/or refractory non-Hodgkin T-cell lymphoma (The LEMONT trial) | PTCL | Maintenance | Phase 2 | 79 | Ongoing | 58 | 11 |
| CISL1705 | CREMA | Combination of rituximab and methotrexate followed by rituximab and cytarabine in elderly patients with primary CNS lymphoma (The CREMA trial) | NHL | 1st-line | Phase 2 | 35 | Published | 36 | 13 |
| CISL1704 | MEITL | Clinicopathologic features of monomorphic epitheliotroic intestinal T-cell lymphoma (MEITL) in Korea: A multicenter, retrospective analysis | PTCL | | Retrosp | 30 | Published | 2 | 1 |
| CISL1703 | PICASSO | Prospective randomized open-labeled phase III study comparing high-dose IV MTX versus IT MTX for the prophylaxis of CNS relapse in DLBCL | DLBCL | 1st-line | Phase 3 | 205 | Closed | 151 | 14 |
| CISL1702 | ASCT-PPX | The incidence rates of fungal / Herpes zoster infections and efficacy of prophylaxis in patients with lymphoma who received autologous stem cell transplantation
| ASCT | | Retrosp | | Published | | |
| CISL1701 | BIC | A Prospective, multi-center, open-label, single-arm, phase II study of bortezomib/dexamethasone therapy in patients with relapsed and/or refractory cutaneous T-cell lymphoma | PTCL | Salvage | Phase 2 | 32 | Closed | 32 | 14 |
| CISL1609 | PROPOSAL | Pralatrexate for Relapsed or Refractory Peripheral T-cell Lymphoma: a Multicenter, Multinational Retrospective Analysis | PTCL | | Retrosp | 50 | Published | | |
| CISL1608 | SATURDAY | Phase 2 Study of Abbreviated 3 Cycles of Rituximab plus CHOP in Patients with Completely Excised Localized Gastrointestinal CD20 (+) Diffuse Large B-cell Lymphoma | DLBCL | 1st-line | Phase 2 | 36 | Closed | 8 | 6 |
| CISL1606 | LITTLE | Retrospective analysis for limited stage (stage ≤2) mantle cell lymphoma | MCL | | Retrosp | 100 | Published | | |
| CISL1604 | BATMAN | A Phase II trial to evaluate the efficacy of bortezomib, cytarabine, and dexamethasone in patients with relapsed or refractory mantle cell lymphoma | MCL | Salvage | Phase 2 | 32 | Closed | 19 | 8 |
| CISL1603 | IVAM | A phase II trial of ifosfamide, etoposide, cytarabine, and methotrexate (IVAM) chemotherapy for refractory or relapsed diffuse large B cell lymphoma | DLBCL | Salvage | Phase 2 | 30 | Closed | | |
| CISL1602 | IVORY | Phase II study of ibrutinib in combination with rituximab-CHOP in Epstein-Barr virus-positive diffuse large B-cell lymphoma | DLBCL | 1st-line | Phase 2 | 24 | Published | | |
| CISL1601 | ICT | Intercontinental Cooperative non-Hodgkin T-cell Lymphoma Prospective Registry Study? | PTCL | Registry | Cohort | 500 | Published | | |
| CISL1600 | SPEED | An Observational Study on Evaluating the Efficacy and Safety of Preemptive Antiviral Therapy with Tenofovir in HBsAg-positive Patients with Diffuse Large B-cell Lymphoma Receiving Rituximab-CHOP Chemotherapy | DLBCL | 1st-line | Cohort | | Published | | |
| CISL1508 | PEL-PBL | Clinical characteristics of primary effusionlymphoma and plasmablastic lymphoma : Therapeutic and prognostic implications | NHL | | Retrosp | 67 | Published | | |
| CISL1507 | BR_PTLD | Multicenter Phase II Study of Bendamustine Plus subcutaneous Rituximab in Patients with Diffuse Large B-cell Lymphoma (DLBCL) Type Monomorphic Post-transplant Lymphoproliferative Disorder (PTLD) | PTLD | 1st-line | Phase 2 | 22 | Closed | | |
| CISL1506 | VIDL+ASCT | Open-labeled, multicenter phase II study of VIDL chemotherapy followed by high-dose chemotherapy and ASCT in patients with stage III/IV extranodal NK/T-cell Lymphoma | NK/T | 1st-line | Phase 2 | 27 | Published | 27 | 9 |
| CISL1505 | Bendamustine | Bendamustine with or without rituximab for relapsed or refractory diffuse large B-cell lymphoma: a multicenter retrospective analysis | DLBCL | | Retrosp | 60 | Published | | |
| CISL1504 | ROSE | Randomized Phase II Study to Compare Efficacy of CHOP versus Fractionated ICED in Transplant-eligible Patients with Previously Untreated Peripheral T-cell Lymphoma | PTCL | 1st-line | Phase 2 | 138 | Closed | 138 | 21 |
| CISL1502 | BENCART | A phase II trial of Bendamustine, carboplatin and dexamethasone (BCD) for refractory or relapsed peripheral T-cell lymphoma | PTCL | Salvage | Phase 2 | 30 | Published | | |
| CISL1501 | Bilateral
OAMZL | Retrospective analysis of treatment outcome for the patients with bilateral ocular adnexal marginal zone lymphoma | MZL | | Retrosp | - | Published | | |
| CISL1406 | BRAN | Brentuximab Vedotin for Relapsed/Refractory CD30-positive Non-Hodgkin Lymphomas | CD30+ | Salvage | Phase 2 | 33 | Published | | |
| CISL1405 | Gastric MALT | Retrospective analysis of the Gastric MALT lymphoma patients who failed Helicobacter pylori eradication | MZL | | Retrosp | - | Closed | | |
| CISL1404 | Giraffe-T | Multicenter Prospective Cohort Study of Peripheral T cell Lymphoma | PTCL | Registry | Cohort | 200 | Published | | |
| CISL1403 | Giraffe-B | Multicenter prospective registry study of diffuse large B cell lymphoma | DLBCL | Registry | Cohort | 1000 | Published | | |
| CISL1402 | EPOMA | A Phase II study of Erythropoietin for management of anemia caused by chemotherapy in patients with DLBL | DLBCL | 1st-line | Phase 2 | 53 | Published | | |
| CISL1401 | GI-FL | Clinical characteristics and outcomes of primary follicular lymphoma of the gastrointestinal tract according to the site of gastrointestinal tract: multicenter retrospective study | FL | | Retrosp | - | Closed | | |
| CISL1308 | PET-PR | Clinical outcomes in patients with DLBCL with a partial response to first-line R-CHOP chemotherapy: prognostic value of secondary International Prognostic Index scores and Deauville scores | DLBCL | | Retrosp | - | Published | | |
| CISL1307 | VRL | Multicenter retrospective analysis of Intraocular lymphoma (Vitreoretinal lymphoma) | MZL | | Retrosp | - | Published | | |
| CISL1306 | JAK2 | Pilot study of ruxolitinib in relapsed or refractory Hodgkin lymphoma and primary mediastinal large B-cell lymphoma | CD30+ | Salvage | Phase 2 | 20 | Published | | |
| CISL1305 | BORMA | Phase II trial: Bortezomib for maintenance therapy in patients with DLBL of high risk | DLBCL | Maintenance | Phase 2 | 59 | Published | | |
| CISL1304 | DLBL-auto | Induction chemotherapy followed by up-front autologous stem cell transplantation may have a survival benefit in high-risk diffuse large B-cell lymphoma patients. | DLBCL | | Retrosp | - | Published | | |
| CISL1302 | Prog-MZL | Prognostic Significance of Neutrophil Lymphocyte Ratio and Platelet Lymphocyte Ratio in Advanced stage Marginal Zone Lymphoma Patients Treated with R-CVP chemotherapy | MZL | | Retrosp | - | Published | | |
| CISL1301 | PINK | A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: a multicentre, retrospective analysis. | NK/T | | Retrosp | 770 | Published | | |
| CISL1210 | PBL | A multicenter retrospective study on clinicopathologic characteristics of Korean patients with plasmablastic lymphoma | NHL | | Retrosp | - | Closed | | |
| CISL1209 | Abb R-CHOP | Phase 2 Study of Abbreviated 3 Cycles of Rituximab plus CHOP in Patients with Completely Excised Stage I or II CD20+ DLBCL | DLBCL | 1st-line | Phase 2 | 23 | Published | | |
| CISL1208 | FOLIK | Retrospective analysis for clinical features and treatment pattern of follicular lymphoma in Korea | FL | | Retrosp | - | Published | | |
| CISL1207 | MARCO | Hepatitis B virus reactivation in patients with marginal zone B-cell lymphoma after rituximab containing treatment: CISL MZL cohort study | MZL | Registry | Cohort | 500 | Closed | 407 | 20 |
| CISL1206 | Elderly DLBCL | Phase II prospective trial of addition of rituximab to reduced dose CHOP chemotherapy in DLBCL patients aged 65 years and over | DLBCL | 1st-line | Phase 2 | 55 | Published | | |
| CISL1205 | BME-BCE | A multicenter randomized phase II trial of ivBuMelEto and ivBuCyEto as the conditioning regimen of ASCT for patients with NHL
| NHL | ASCT | Phase 2 | 78 | Published | | |
| CISL1204 | Hyper-CVAD | The clinical outcomes of Hyper-CVAD treatment in lymphoblastic lymphoma | LL | | Retrosp | - | Published | | |
| CISL1203 | Burkitt | Treatment Outcomes of Rituximab Plus Hyper-CVAD in Korean Patients with Sporadic Burkitt or Burkitt-like Lymphoma | BL | | Retrosp | - | Published | | |
| CISL1202 | PBSCH | High Dose Etoposide Plus G-CSF as an Effective Mobilization Regimen In Patients with NHL Previously Treated with R-CHOP or CHOP Chemotherapy. Retrospective Multicenter Study. | NHL | | Retrosp | 119 | Published | | |
| CISL1201 | V-FND | Results of a phase II study of vorinostat in combination with intravenous fludarabine, mitoxantrone, and dexamethasone in patients with relapsed or refractory mantle cell lymphoma | MCL | Salvage | Phase 2 | 48 | Published | | |
| CISL1111 | BM | Clinical significance of cytogenetic aberrations in bone marrow of patients with DLBCL: prognostic significance and pelevance to histologic involvement | DLBCL | | Retrosp | 46 | Published | | |
| CISL1110 | Wal-MZL | Retrospective study on Waldeyer’s ring MZL | MZL | | Retrosp | | Published | | |
| CISL1109 | PTCL-Px | Lymphopenia is an important prognostic factor in peripheral T-cell lymphoma (NOS) treated with anthracycline-containing chemotherapy. | PTCL | | Retrosp | 118 | Published | | |
| CISL1108 | RAD-CHOP | A phase I/II study of RAD001 combined with CHOP in newly diagnosed peripheral T-cell lymphomas | PTCL | 1st-line | Phase 2 | 46 | Published | | |
| CISL1107 | PROCESS-BM | BM involvement from prospective cohort (PROCESS) | DLBCL | Registry | Cohort | - | Published | | |
| CISL1106 | Breast DLBCL | Multi-center Phase II Study evaluating the efficacy and safety of the Combination of R-CHOP and Prophylactic Intrathecal Chemotherapy with Methotrexate in Patients with CD20+ Primary Breast DLBCL | DLBCL | 1st-line | Phase 2 | 33 | Published | | |
| CISL1105 | Wal-NHL | Multicenter retrospective analysis about the clinical features and treatment outcome for waldeyer’s ring lymphoma | NHL | | Retrosp | - | Published | | |
| CISL1104 | adrenal DLBCL | Prognostic factors in primary diffuse large B-cell lymphoma of adrenal gland treated with rituximab- CHOP chemotherapy from the Consortium for Improving Survival of Lymphoma (CISL) | DLBCL | | Retrosp | 50 | Published | | |
| CISL1103 | Sinonasal DLBLC | Sinonasal Diffuse Large B Cell Lymphoma treated with R-CHOP : Treatment outcome and Prognosis | DLBCL | | Retrosp | 40 | Published | | |
| CISL1102 | local MZBL | Stage I/II marginal zone B-cell lymphoma- Multicenter retrospective analysis of 217 cases | MZL | | Retrosp | 217 | Published | | |
| CISL1101 | Cuteneous NKT | Extranodal natural killer/T-cell lymphoma from skin or soft tissue: suggestion of treatment from multinational retrospective analysis. | NK/T | | Retrosp | 48 | Published | | |
| CISL1017 | Intestinal NHL | Multicenter retrospective analysis of 581 patients with primary intestinal non-hodgkin lymphoma from the Consortium for Improving Survival of Lymphoma (CISL). | NHL | | Retrosp | 581 | Published | | |
| CISL1016 | Intestinal DLBCL | Comparison of treatment strategies for patients with intestinal diffuse large B-cell lymphoma: surgical resection followed by chemotherapy versus chemotherapy alone. | DLBCL | | Retrosp | 345 | Published | | |
| CISL1015 | HL | Clinical features and outcomes of Hodgkin's lymphoma in Korea: Consortium for Improving Survival of Lymphoma (CISL). | HL | | Retrosp | 539 | Published | | |
| CISL1014 | Advanced MZL | Stage IV marginal zone B-cell lymphoma--prognostic factors and the role of rituximab: Consortium for Improving Survival of Lymphoma (CISL) study. | MZL | | Retrosp | 94 | Published | | |
| CISL1013 | Salvage-RI | Repeated radioimmunotherapy with 131I-rituximab for patients with low-grade and aggressive relapsed or refractory B cell non-Hodgkin lymphoma | DLBCL | Salvage | Phase 2 | - | Published | | |
| CISL1012 | Breast DLBCL | Matched-pair analysis comparing the outcomes of primary breast and nodal diffuse large B-cell lymphoma in patients treated with rituximab plus chemotherapy. | DLBCL | | Retrosp | 25 | Published | | |
| CISL1011 | ESHAOx | A multicenter phase II study of etoposide, methylprednisolone, high-dose cytarabine and oxaliplatin (ESHAOx) for patients with refractory or relapsed Hodgkin’s lymphoma (HL) | HL | Salvage | Phase 2 | 37 | Published | | |
| CISL1010 | OAML | Open-labeled, multicenter phase II study of rituximab, cyclophosphamide, vincristine, and prednisolone (R-CVP) chemotherapy in patients with non-conjunctival ocular adnexal MALT lymphoma | MZL | 1st-line | Phase 2 | 33 | Published | | |
| CISL1009 | R-maintanence | R-CVP followed by Rituximab maintenance therapy for patients with Advanced Marginal Zone B-cell Lymphoma | MZL | Maintenance | Phase 2 | 48 | Published | | |
| CISL1008 | MIDLE | Phase II trial of concurrent chemoradiotherapy with L-asparaginase and MIDLE chemotherapy for newly diagnosed stage I/II extranodal NK/T-cell lymphoma, nasal type | NK/T | 1st-line | Phase 2 | 30 | Published | | |
| CISL1007 | C.jejuni MZL | Relationship Between Intestinal Marginal Zone B-Cell Lymphoma and Enterobacterias Including Camphylobacter Jejuni | MZL | | Retrosp | 33 | Closed | | |
| CISL1006 | PROCESS | Prospective Cohort Study with Risk-adapted Central Nervous System Evaluation in Diffuse Large B-cell Lymphoma | DLBCL | Registry | Cohort | 600 | Published | | |
| CISL1005 | Thyroid MZL | Primary Thyroid Marginal Zone B-Cell Lymphoma of the Mucosa-Associated Lymphoid Tissue Type: Clinical Manifestation and Outcome of a Rare Disease ? Consortium for Improving Survival of Lymphoma Study | MZL | | Retrosp | 27 | Published | | |
| CISL1004 | R-consolidation | Weekly rituximab consolidation following four cycles of R-CHOP induction chemotherapy in very elderly patients with diffuse large B-cell lymphoma: Consortium for improving survival of lymphoma study (CISL). | DLBCL | 1st-line | Phase 2 | 66 | Published | | |
| CISL1003 | GDP | A Phase II trial of Gemcitabine, dexamethasone and cisplatin (GDP) for refractory or relapsed peripheral T-cell lymphoma | PTCL | Salvage | Phase 2 | 27 | Published | | |
| CISL1002 | MCL | Clinical features and treatment outcomes in patients with mantle cell lymphoma in Korea: Study by the Consortium for Improving Survival of Lymphoma. | MCL | | Retrosp | - | Published | | |
| CISL1001 | PCNSL | Open-labeled, multicenter phase II study of HD MTX induction chemotherapy followed by alternative HD MTX-based and HD Cytarabine-based combination consolidation chemotherapy for newly diagnosed primary CNS lymphoma | NHL | 1st-line | Phase 2 | 51 | Closed | | |
| CISL0909 | NG-MZL | Non-gastric marginal zone B-cell lymphoma in Korea: clinical features, treatment, and prognostic factors. | MZL | | Retrosp | 505 | Published | | |
| CISL0908 | Ovary NHL | Clinical features and prognostic relevance of ovarian involvement in non-Hodgkin's lymphoma: A Consortium for Improving Survival of Lymphoma (CISL) report. | NHL | | Retrosp | 18 | Published | | |
| CISL0907 | BALT | Pulmonary marginal zone B-cell lymphoma of MALT type--what is a prognostic factor and which is the optimal treatment, operation, or chemotherapy? | MZL | | Retrosp | 61 | Published | | |
| CISL0906 | CNS prophylaxis | When do we need central nervous system prophylaxis in patients with extranodal NK/T-cell lymphoma, nasal type? | NK/T | | Retrosp | 208 | Published | | |
| CISL0905 | Ox-P | A phase II study of Oxaliplatin and Prednisolone (Ox-P) for patients with relapsed or refractory marginal zone B-cell lymphoma | MZL | Salvage | Phase 2 | 38 | Published | | |
| CISL0904 | ASCT | Retrospective analysis of effective conditioning regimens for autologous stem cell transplantation in NHL | NHL | | Retrosp | 340 | Closed | | |
| CISL0903 | Breast DLBCL | Clinical outcomes and prognostic factors in patients with breast diffuse large B cell lymphoma; Consortium for Improving Survival of Lymphoma (CISL) study. | DLBCL | | Retrosp | 68 | Published | | |
| CISL0902 | Multi-MALT | Multiple mucosa-associated lymphoid tissue organs involving marginal zone B cell lymphoma: organ-specific relationships and the prognostic factors. Consortium for improving survival of lymphoma study. | MZL | | Retrosp | 55 | Published | | |
| CISL0901 | BuMelEto | Open-labelled, Multicenter Phase II Clinical Trial of intravenous busulfan, melphalan and etoposide as conditioning for autologous transplantation in patients with high-risk, refractory or relapsed non-Hodgkin’s lymphoma | NHL | ASCT | Phase 2 | 51 | Published | | |
| CISL0900 | Alem PTCL | Non-bacterial infections in Asian patients treated with alemtuzumab: a retrospective study of the Asian Lymphoma Study Group. | PTCL | | Retrosp | 182 | Published | | |
| CISL0806 | BuMelThio | Multicenter Phase II Clinical Trial of intravenous busulfan, melphalan and thiotepa as conditioning for autologous transplantation in non-Hodgkin’s lymphoma | NHL | ASCT | Phase 2 | 13 | Published | | |
| CISL0805 | NG-MZL | Relapsed or refractory nongastric marginal zone B-cell lymphoma: multicenter retrospective analysis of 92 cases. | MZL | | Retrosp | 92 | Published | | |
| CISL0804 | LL | Clinical features and treatment outcomes of adult B- and T-lymphoblastic lymphoma: results of multicentre analysis in Korea. | LL | | Retrosp | 55 | Published | | |
| CISL0803 | RR-CHOP | Open-labelled, Multicenter Phase II Study of Intensified 1st cycle Rituximab plus 8th cycles of R-CHOP Chemotherapy in Patients with Advanced or Bulky CD20+ DLBCL | DLBCL | 1st-line | Phase 2 | 91 | Closed | | |
| CISL0802 | ESHAOX | A multicenter phase II trial of etoposide, methylprednisolone, high-dose cytarabine, and oxaliplatin for patients with primary refractory/relapsed aggressive non-Hodgkin's lymphoma. | DLBCL | Salvage | Phase 2 | 27 | Published | | |
| CISL0801 | VIDL | Open-labeled, multicenter phase II study of concomitant chemo-radiotherapy followed by VIDL chemotherapy with risk-based application of autologous stem cell transplantation in stage I/II Extranodal NK/T-cell Lymphoma | NK/T | 1st-line | Phase 2 | 30 | Published | | |
| CISL0705 | Vel-CHOP2 | Bortezomib in combination with CHOP as first-line treatment for patients with stage III/IV peripheral T-cell lymphomas: a multicentre, single-arm, phase 2 trial. | PTCL | 1st-line | Phase 2 | 46 | Published | | |
| CISL0704 | NG-MZL | Nongastric marginal zone B-cell lymphoma: a prognostic model from a retrospective multicenter study. | MZL | | Retrosp | 505 | Published | | |
| CISL0703 | Intestinal MZL | Intestinal marginal zone B-cell lymphoma of MALT type: clinical manifestation and outcome of a rare disease. | MZL | | Retrosp | 27 | Published | | |
| CISL0702 | GIDOX | Salvage therapy with gemcitabine, ifosfamide, dexamethasone, and oxaliplatin (GIDOX) for B-cell non-Hodgkin's lymphoma: a consortium for improving survival of lymphoma (CISL) trial. | DLBCL | Salvage | Phase 2 | 27 | Published | | |
| CISL0701 | Vel-CHOP | Phase I study of proteasome inhibitor bortezomib plus CHOP in patients with advanced, aggressive T-cell or NK/T-cell lymphoma. | PTCL | 1st-line | Phase 1 | 13 | Published | | |
| CISL0609 | NG-MZL | Nongastric marginal zone B-cell lymphoma: analysis of 247 cases. | MZL | | Retrosp | 247 | Published | | |
| CISL0608 | nodal MZL | Nodal marginal zone B-cell lymphoma: Analysis of 36 cases. Clinical presentation and treatment outcomes of nodal marginal zone B-cell lymphoma. | MZL | | Retrosp | 36 | Published | | |
| CISL0607 | RI-con | Pilot trial of yttrium-90 ibritumomab tiuxetan consolidation following R-CHOP in patients with limited-stage, bulky DLBCL. | DLBCL | 1st-line | Phase 2 | 21 | Published | | |
| CISL0606 | Gem/MZL | Phase II study of gemcitabine for treatment of patients with advanced stage marginal zone B-cell lymphoma: Consortium for Improving Survival of Lymphoma (CISL) trial. | MZL | 1st-line | Phase 2 | 16 | Published | | |
| CISL0605 | R-CVP | Phase II trial of rituximab plus CVP combination chemotherapy for advanced stage marginal zone lymphoma as a first-line therapy: Consortium for Improving Survival of Lymphoma (CISL) study. | MZL | 1st-line | Phase 2 | 42 | Published | | |
| CISL0604 | A-DHAP | Alemtuzumab and DHAP (A-DHAP) is effective for relapsed peripheral T-cell lymphoma, unspecified: interim results of a phase II prospective study. | PTCL | Salvage | Phase 2 | 16 | Published | | |
| CISL0603 | Vel-CHOP | A phase I/II study of bortezomib plus CHOP every 2 weeks (CHOP-14) in patients with advanced-stage diffuse large B-cell lymphomas. | DLBCL | 1st-line | Phase 2 | 49 | Published | | |
| CISL0602 | RI | Radioimmunotherapy with (131)I-rituximab for patients with relapsed/refractory B-cell non-Hodgkin's lymphoma (NHL). | DLBCL | Salvage | Phase 2 | 24 | Published | | |
| CISL0601 | VIPD | Phase II trial of concurrent radiation and weekly cisplatin followed by VIPD chemotherapy in newly diagnosed, stage IE to IIE, nasal, extranodal NK/T-Cell Lymphoma: Consortium for Improving Survival of Lymphoma study. | NK/T | 1st-line | Phase 2 | 30 | Published | | |
| CISL | PMBCL | Real-world outcomes of patients with primary mediastinal large B-cell lymphoma in Korea: A multicenter, retrospective analysis
| PMBCL | Registry | Retrosp | 00 | Ongoing | | |
| | | | | | | Published | | |